Nothing Special   »   [go: up one dir, main page]

HRP20240996T1 - Prefuzija rsv f proteina i njihova uporaba - Google Patents

Prefuzija rsv f proteina i njihova uporaba Download PDF

Info

Publication number
HRP20240996T1
HRP20240996T1 HRP20240996TT HRP20240996T HRP20240996T1 HR P20240996 T1 HRP20240996 T1 HR P20240996T1 HR P20240996T T HRP20240996T T HR P20240996TT HR P20240996 T HRP20240996 T HR P20240996T HR P20240996 T1 HRP20240996 T1 HR P20240996T1
Authority
HR
Croatia
Prior art keywords
protein
seq
rsv
immunogen
subtype
Prior art date
Application number
HRP20240996TT
Other languages
English (en)
Inventor
Jeffrey Boyington
Ivelin Stefanov Georgiev
Marie PANCERA
Cinque SOTO
Sanjay SRIVATSAN
Guillaume Stewart-Jones
Peter D. Kwong
Barney S. Graham
Jason S. MCLELLAN
Michael Gordon Joyce
Masaru Kanekiyo
Baoshan Zhang
Lei Chen
Man Chen
Gwo-yu CHUANG
Jason Gorman
Yongping Yang
Tongqing Zhou
Mallika SASTRY
Gilad Ofek
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of HRP20240996T1 publication Critical patent/HRP20240996T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)

Claims (30)

1. Izolirani imunogen, koji sadrži: rekombinantni RSV F protein ili njegov fragment koji sadrži aminokiselinske supstitucije u usporedbi s nativnim RSV F proteinom kako je navedeno kao jedan od SEQ ID NO: 1-184 koji stabilizira rekombinantni RSV F protein u prefuzijskoj konformaciji koja se specifično veže na RSV F antitijelo specifično za prefuziju, naznačen time što: rekombinantni RSV F protein je stabiliziran u konformaciji RSV F proteina prefuzije supstitucijama S155C, S290C, S190F i V207L, prefuzijska konformacija rekombinantnog RSV F proteina ili njegovog fragmenta sadrži antigensko mjesto Ø koje sadrži ostatke 62-69 i 196-209 nativnog RSV F proteinskog slijeda navedenog kao jedan od SEQ ID NO: 1-184, imunogen se specifično veže na protutijelo specifično za prefuziju nakon inkubacije na 20°C u fiziološkoj otopini s fosfatnim puferom pri fiziološkom pH najmanje 24 sata u odsutnosti protutijela specifičnog za prefuziju, i antitijelo specifično za RSV F prefuziju ne veže se na RSV F protein u postfuzijskoj konformaciji; i antitijelo specifično za prefuziju je D25 antitijelo koje sadrži VH i VL domene kao što je navedeno u SEQ ID NOs 368 i 369, redom.
2. Imunogen prema zahtjevu 1, naznačen time što rekombinantni RSV F protein sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-513, odnosno 26-103 i 145-513. , odnosno 26-105 i 145-513, redom, jednog od SEQ ID NO: 371 (DS-Cav1, podtip A), 372 (DSCav1, podtip B) ili 373 (DSCav1, govedo).
3. Imunogen prema zahtjevu 2, naznačen time što rekombinantni RSV F protein sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-513, odnosno 26-103 i 145-513. , odnosno 26-105 i 145-513, redom, jednog od SEQ ID NO: 371 (DS-Cav1, podtip A).
4. Imunogen prema zahtjevu 2, naznačen time što rekombinantni RSV F protein sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-513, odnosno 26-103 i 145-513. , odnosno 26-105 i 145-513, redom, jednog od SEQ ID NO: 372 (DS-Cav1, podtip B).
5. Imunogen prema zahtjevu 2, naznačen time što rekombinantni RSV F protein sadrži ostatke 26-109 i 137-513, odnosno 26-103 i 145-513, odnosno 26-105 i 145-513, redom, jednog od SEQ ID NO: 371 (DS-Cav1, podtip A).
6. Imunogen prema zahtjevu 2, naznačen time što rekombinantni RSV F protein sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-513, odnosno 26-103 i 145-513. , odnosno 26-105 i 145-513, redom, jednog od SEQ ID NO: 372 (DSCav1, podtip B).
7. Imunogen prema bilo kojem od prethodnih zahtjeva, koji sadrži multimer rekombinantnog RSV F proteina ili njegov fragment prema zahtjevima 1-7.
8. Imunogen prema bilo kojem od prethodnih zahtjeva, naznačen time što je rekombinantni RSV F protein ili njegov fragment prema zahtjevima 1-7 vezan na trimerizacijsku domenu.
9. Imunogen prema zahtjevu 8, naznačen time što je C-kraj F1 polipeptida rekombinantnog RSV F proteina vezan na trimerizacijsku domenu.
10. Imunogen prema zahtjevu 8 ili zahtjevu 9, naznačen time što je trimerizacijska domena Foldonova domena.
11. Imunogen prema zahtjevu 8, naznačen time što rekombinantni RSV F protein vezan na trimerizacijsku domenu sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-544 ili 26-103 i 145-544 jedne od SEQ ID NO: 371 (DS-Cav1, podtip A), 372 (DSCav1, podtip B) ili 373 (DSCav1, govedo).
12. Imunogen prema zahtjevu 11, naznačen time što rekombinantni RSV F protein vezan na trimerizacijsku domenu sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-544 ili 26-103 i 145-544 jedne od SEQ ID NO: 371 (DS-Cav1, podtip A).
13. Imunogen prema zahtjevu 11, naznačen time što rekombinantni RSV F protein sadrži ili se sastoji od aminokiselinske sekvence koja sadrži najmanje 80% identičnosti s ostacima 26-109 i 137-544, odnosno 26-103 i 145-544. , odnosno 26-105 i 145-513, redom, jednog od SEQ ID NO: 372 (DS-Cav1, podtip B).
14. Imunogen prema zahtjevu 11, naznačen time što rekombinantni RSV F protein vezan na trimerizacijsku domenu sadrži ostatke 26-109 i 137-544 ili 26-103 i 145-544 SEQ ID NO: 371 (DS-Cav1, podtip A).
15. Imunogen prema zahtjevu 11, naznačen time što rekombinantni RSV F protein vezan na trimerizacijsku domenu sadrži ostatke 26-109 i 137-544 ili 26-103 i 145-544 SEQ ID NO: 372 (DS-Cav1, podtip B).
16. Virusu slična čestica koja sadrži imunogen prema bilo kojem od zahtjeva 1-15.
17. Virusu slična čestica koja sadrži imunogen prema bilo kojem od zahtjeva 1-15.
18. Virusu slična čestica koja sadrži imunogen prema bilo kojem od zahtjeva 1-17.
19. Molekula nukleinske kiseline prema zahtjevu 18, operativno povezana na promotor.
20. Vektor koji sadrži molekulu nukleinske kiseline prema zahtjevu 19.
21. Vektor prema zahtjevu 20, naznačen time što je vektor virusni vektor.
22. Molekula nukleinske kiseline ili vektor prema bilo kojem od zahtjeva 19-21, naznačena time što sadrži nukleotidnu sekvencu navedenu kao SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385 ili SEQ ID NO: 386.
23. Imunogeni pripravak koji sadrži učinkovitu količinu imunogena, čestice slične virusu, proteinske nanočestice, molekule nukleinske kiseline, ili vektora prema bilo kojem od zahtjeva 1-22; i farmaceutski prihvatljiv nosač.
24. Imunogeni pripravak prema zahtjevu 23 za uporabu u postupku za generiranje imunološkog odgovora na RSV F kod subjekta kojem je to potrebno, koji se sastoji od davanja subjektu učinkovite količine imunogenog pripravka za generiranje imunološkog odgovora.
25. Imunogeni pripravak za uporabu prema zahtjevu 24, naznačen time što postupak sadrži primarno pojačano davanje imunogenog pripravka.
26. Imunogeni pripravak za uporabu prema zahtjevu 24 ili 25, naznačen time što je ljudski ili veterinarski subjekt.
27. Imunogeni pripravak za uporabu prema bilo kojem od zahtjeva 25-26, naznačen time što je subjekt mlađi od jedne godine, stariji od 65 godina, ili je trudan.
28. Komplet koji sadrži imunogen, česticu sličnu virusu, proteinsku nanočesticu, molekulu nukleinske kiseline, vektor, stanicu domaćina, ili imunogeni pripravak prema bilo kojem od zahtjeva 1-27; i upute za korištenje kompleta.
29. Imunogen prema bilo kojem od zahtjeva 1-15, za uporabu za inhibiciju RSV infekcije kod subjekta.
30. Imunogen prema bilo kojem od zahtjeva 1-15, za uporabu u postupku indukcije imunološkog odgovora na RSV F protein kod subjekta kojem je to potrebno.
HRP20240996TT 2013-03-13 2014-03-13 Prefuzija rsv f proteina i njihova uporaba HRP20240996T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361780910P 2013-03-13 2013-03-13
US201361798389P 2013-03-15 2013-03-15
US201361857613P 2013-07-23 2013-07-23
US201361863909P 2013-08-09 2013-08-09
EP14775224.0A EP2970398B1 (en) 2013-03-13 2014-03-13 Prefusion rsv f proteins and their use
PCT/US2014/026714 WO2014160463A1 (en) 2013-03-13 2014-03-13 Prefusion rsv f proteins and their use

Publications (1)

Publication Number Publication Date
HRP20240996T1 true HRP20240996T1 (hr) 2024-10-25

Family

ID=51625430

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240996TT HRP20240996T1 (hr) 2013-03-13 2014-03-13 Prefuzija rsv f proteina i njihova uporaba

Country Status (20)

Country Link
US (4) US10017543B2 (hr)
EP (2) EP2970398B1 (hr)
JP (4) JP6703475B2 (hr)
KR (2) KR20220139415A (hr)
CN (2) CN105473604B (hr)
AU (4) AU2014243756B2 (hr)
CA (1) CA2902877A1 (hr)
DK (1) DK2970398T3 (hr)
ES (1) ES2981623T3 (hr)
FI (1) FI2970398T3 (hr)
HR (1) HRP20240996T1 (hr)
HU (1) HUE067333T2 (hr)
LT (1) LT2970398T (hr)
MX (2) MX2015013065A (hr)
PL (1) PL2970398T3 (hr)
PT (1) PT2970398T (hr)
RS (1) RS65760B1 (hr)
RU (2) RU2021132097A (hr)
SI (1) SI2970398T1 (hr)
WO (1) WO2014160463A1 (hr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
ES2778899T3 (es) 2013-02-01 2020-08-12 Medimmune Llc Epítopos de proteína F del virus sincitial respiratorio
PL2970398T3 (pl) * 2013-03-13 2024-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Białka f rsv przed fuzją i ich zastosowanie
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2970981B1 (en) 2013-03-14 2020-10-28 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
LT2988780T (lt) 2013-04-25 2019-03-12 Janssen Vaccines & Prevention B.V. Stabilizuoti tirpūs rsv f polipeptidai prieš suliejimą
MX362792B (es) 2013-06-17 2019-02-13 Janssen Vaccines & Prevention Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3677279A1 (en) 2013-07-25 2020-07-08 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
EP3049107A1 (en) * 2013-09-24 2016-08-03 Massachusetts Institute of Technology Self-assembled nanoparticle vaccines
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP7020917B2 (ja) 2015-01-20 2022-02-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ キメラｒｓｖ／ｂｐｉｖ３ ｆタンパクを発現する組換えヒト／ウシパラインフルエンザウイルス３（ｂ／ｈｐｉｖ３）およびその使用
EP3250233A4 (en) * 2015-01-29 2018-07-25 Agency for Science, Technology and Research Nanocapsules carrying chikungunya-associated peptides
EA035909B1 (ru) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
EA039065B1 (ru) * 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
FR3041962B1 (fr) * 2015-10-01 2018-01-05 Lab Francais Du Fractionnement Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie
PL3718565T3 (pl) 2015-10-22 2022-09-19 Modernatx, Inc. Szczepionki przeciwko wirusom układu oddechowego
BR112018008102A2 (pt) * 2015-10-22 2018-11-06 Modernatx Inc vacina de vírus sincicial respiratório
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
EP3393512A1 (en) * 2015-12-23 2018-10-31 Pfizer Inc Rsv f protein mutants
KR102464372B1 (ko) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
MA43762A (fr) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv Vaccin contre le rsv
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN106119287B (zh) * 2016-08-29 2019-10-11 广东华南疫苗股份有限公司 一种表达呼吸道合胞病毒f蛋白的重组载体及方法
WO2018067300A1 (en) 2016-10-03 2018-04-12 University Of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
EP3532096B1 (en) 2016-10-25 2023-02-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion piv f immunogens and their use
SG11201903737PA (en) * 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018175518A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
CN115779077A (zh) 2017-04-04 2023-03-14 华盛顿大学 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
GB2577232B (en) 2017-05-30 2022-07-06 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
RU2019142012A (ru) * 2017-06-14 2021-07-14 Вирометикс Аг Циклические пептиды для защиты от респираторно-синцитиального вируса
US11267848B2 (en) 2017-08-07 2022-03-08 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
JP2019092481A (ja) * 2017-11-27 2019-06-20 国立大学法人東京工業大学 ヘテロタンパク質ケージ
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
WO2019147749A2 (en) 2018-01-29 2019-08-01 Merck Sharp & Dohme Corp. Stabilized rsv f proteins and uses thereof
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
WO2019178521A1 (en) * 2018-03-16 2019-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncitial virus infection
CN112512565A (zh) * 2018-04-03 2021-03-16 赛诺菲 抗原性流感-铁蛋白多肽
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
BR112020019938A2 (pt) * 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
WO2019195316A1 (en) * 2018-04-03 2019-10-10 Sanofi Ferritin proteins
MX2020010941A (es) 2018-04-17 2021-01-29 Curevac Ag Moleculas y composiciones novedosas de arn de vsr para vacunacion.
CN112585165A (zh) 2018-04-25 2021-03-30 普罗米修斯生物科学公司 优化的抗tl1a抗体
SG11202010821TA (en) 2018-05-04 2020-11-27 Spybiotech Ltd Vaccine composition
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
SG11202100194VA (en) 2018-07-31 2021-02-25 Glaxosmithkline Biologicals Sa Antigen purification method
CN112930192A (zh) 2018-08-03 2021-06-08 美国政府(由卫生和人类服务部的部长所代表) 尼帕病毒免疫原及其用途
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
US20220017574A1 (en) * 2018-11-13 2022-01-20 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CA3120102A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Engineered cd25 polypeptides and uses thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
KR102679227B1 (ko) 2019-02-28 2024-06-28 케이엠 바이올로직스 가부시키가이샤 Rsv f/g 키메라 백신
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
EP4072581A1 (en) 2019-12-11 2022-10-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Mumps and measles virus immunogens and their use
IL294059A (en) * 2019-12-23 2022-08-01 Mitsubishi Tanabe Pharma Corp Mutant rsv f protein and its use
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CA3169664A1 (en) * 2020-01-30 2021-08-05 Modernatx, Inc. Respiratory virus immunizing compositions
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
US20230174587A1 (en) * 2020-04-29 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human metapneumovirus f proteins and their use
CA3170740A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
EP4157345A4 (en) * 2020-05-29 2024-09-11 Univ Texas MANIPULATED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
AU2021357826A1 (en) 2020-10-09 2023-05-11 Board Of Regents, The University Of Texas System Prefusion-stabilized hmpv f proteins
JP2023547197A (ja) 2020-10-28 2023-11-09 サノフィ・パスツール Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用
CN112592928B (zh) * 2020-12-31 2021-08-31 北京鼎成肽源生物技术有限公司 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法
WO2022175477A1 (en) * 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
AU2022251938A1 (en) 2021-04-02 2023-11-16 Bureau D’Études Biologiques Scientifiques Et Médicales IMMUNOGENIC COMPOSITION CONTAINING AN ANTIGEN AND AN ADJUVANT COMPRISING AL-MOFs
US20220324917A1 (en) * 2021-04-12 2022-10-13 Sk Bioscience Co., Ltd. Recombinant rsv live vaccine strain and the preparing method thereof
US20240200099A1 (en) * 2021-04-15 2024-06-20 Merck Sharp & Dohme Llc Rotavirus vectors for heterologous gene delivery
MX2024001867A (es) * 2021-08-10 2024-03-04 Icosavax Inc Vacuna de particulas similares a virus para el virus respiratorio sincitial.
JP2024536236A (ja) * 2021-09-29 2024-10-04 エスケー バイオサイエンス カンパニー リミテッド 組み換えられた弱毒化ｒｓｖ生ワクチン及びその製造方法
WO2023208206A1 (zh) * 2022-04-29 2023-11-02 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
TW202408543A (zh) * 2022-05-31 2024-03-01 日商Ｖｌｐ醫療日本股份有限公司 改良疫苗設計發展
WO2023237649A1 (en) * 2022-06-10 2023-12-14 Glaxosmithkline Biologicals Sa Rsv vaccination with trimeric rsv f fusion protein
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
TW202424187A (zh) 2022-10-27 2024-06-16 美商輝瑞大藥廠 Rna分子
WO2024094881A1 (en) * 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
WO2024100196A1 (en) * 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
KR102531775B1 (ko) 2022-11-11 2023-05-15 대한민국 Rsv f 항체 또는 이의 항원 결합 단편
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
WO2024115561A1 (en) * 2022-12-01 2024-06-06 Glaxosmithkline Biologicals Sa Vaccination against rsv
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
WO2024155561A2 (en) * 2023-01-17 2024-07-25 The Scripps Research Institute Engineered paramyxovirus soluble fusion (f) proteins and related vaccines
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
WO2024175579A1 (en) * 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
WO2024175040A1 (en) * 2023-02-22 2024-08-29 Everest Medicines (China) Co., Ltd. RSV mRNA VACCINES
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
CN116536357A (zh) * 2023-04-17 2023-08-04 中国医学科学院输血研究所 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法
CN118108812A (zh) * 2023-05-04 2024-05-31 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117586425B (zh) * 2024-01-19 2024-06-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用
CN117586357B (zh) * 2024-01-19 2024-07-09 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN118440937A (zh) * 2024-04-09 2024-08-06 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US472209A (en) 1892-04-05 Vacuum-pan
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1336955C (en) * 1988-09-20 1995-09-12 Peter R. Paradiso Respiratory syncytial virus: vaccines and diagnostic assays
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE399873T1 (de) 1993-07-13 2008-07-15 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JP2002511771A (ja) * 1998-06-10 2002-04-16 インサイト・ファーマスーティカルズ・インコーポレイテッド 新規なカルボキシペプチダーゼインヒビター
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
EP2119793A1 (en) 2000-06-28 2009-11-18 Glycofi, Inc. Methods for producing modified glycoproteins
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
ATE489968T1 (de) 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
CN1250548C (zh) 2001-04-17 2006-04-12 大日本住友制药株式会社 新的腺嘌呤衍生物
CA2454992A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
US7041489B2 (en) 2001-10-01 2006-05-09 The Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof
PT1719511E (pt) 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
CA2477234C (en) 2002-02-21 2014-12-30 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
WO2004010935A2 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
KR20050073559A (ko) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 당단백질 합성
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US20050142148A1 (en) 2003-04-25 2005-06-30 Fouchier Ronaldus A.M. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2523319A1 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2005111621A2 (en) 2004-04-16 2005-11-24 Uab Research Foundation Molecular scaffolds for hiv-1 epitopes
WO2006091455A2 (en) 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
US20060216700A1 (en) 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7728106B2 (en) 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US20100068217A1 (en) 2006-08-25 2010-03-18 Kwong Peter D Epitope-transplant scaffolds and their use
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20090017517A1 (en) 2007-07-13 2009-01-15 Medimmune, Llc Preparation of Negative-Stranded RNA Viruses by Electroporation
DK2222710T3 (en) * 2007-12-24 2016-10-03 Id Biomedical Corp Quebec Recombinant RSV antigens.
CN103255169A (zh) 2007-12-27 2013-08-21 苏黎士大学 复制缺陷型沙粒病毒载体
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
RU2560976C2 (ru) 2009-05-12 2015-08-20 Трансген Са Способ продуцирования и очистки ортопоксвируса
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
CA2766205A1 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
HUE058971T2 (hu) 2009-07-15 2022-09-28 Glaxosmithkline Biologicals Sa RSV F fehérjekészítmények és eljárások azok elõállítására
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CA2776249C (en) 2009-10-06 2021-01-19 Medimmune Ltd Rsv-specific binding molecule
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
PL3275892T3 (pl) * 2011-05-13 2020-09-07 Glaxosmithkline Biologicals S.A. Przedfuzyjne antygeny RSV F
CN102210860B (zh) 2011-05-31 2012-11-21 昆明理工大学 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
SG11201500573RA (en) * 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
CA2890135A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Biologicals S.A. Rsv f prefusion trimers
PL2970398T3 (pl) * 2013-03-13 2024-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Białka f rsv przed fuzją i ich zastosowanie
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6462599B2 (ja) 2013-03-15 2019-01-30 シャアメン ユニバーシティ Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
LT2988780T (lt) 2013-04-25 2019-03-12 Janssen Vaccines & Prevention B.V. Stabilizuoti tirpūs rsv f polipeptidai prieš suliejimą

Also Published As

Publication number Publication date
ES2981623T3 (es) 2024-10-10
KR20150127102A (ko) 2015-11-16
AU2018282476A1 (en) 2019-01-24
CN112851766A (zh) 2021-05-28
RU2015142981A3 (hr) 2018-03-14
KR102450375B1 (ko) 2022-10-04
AU2023200712A1 (en) 2023-03-09
DK2970398T3 (da) 2024-08-05
RU2761631C2 (ru) 2021-12-13
KR20220139415A (ko) 2022-10-14
CN105473604B (zh) 2021-01-22
JP2016519658A (ja) 2016-07-07
US20180319846A1 (en) 2018-11-08
US20160046675A1 (en) 2016-02-18
CA2902877A1 (en) 2014-10-02
RU2015142981A (ru) 2017-04-17
FI2970398T3 (fi) 2024-08-06
RS65760B1 (sr) 2024-08-30
SI2970398T1 (sl) 2024-09-30
AU2014243756B2 (en) 2018-09-27
US10017543B2 (en) 2018-07-10
WO2014160463A1 (en) 2014-10-02
JP7503588B2 (ja) 2024-06-20
BR112015022375A2 (pt) 2017-10-10
EP2970398A4 (en) 2016-08-24
LT2970398T (lt) 2024-08-12
BR112015022375A8 (pt) 2018-01-23
EP2970398A1 (en) 2016-01-20
JP2020089384A (ja) 2020-06-11
US11981707B2 (en) 2024-05-14
EP2970398B1 (en) 2024-05-08
AU2018282476B2 (en) 2020-12-10
JP2022089818A (ja) 2022-06-16
US11130785B2 (en) 2021-09-28
JP2024107243A (ja) 2024-08-08
JP6703475B2 (ja) 2020-06-03
AU2014243756A1 (en) 2015-09-17
CN105473604A (zh) 2016-04-06
JP7043530B2 (ja) 2022-03-29
MX2021010519A (es) 2021-10-01
AU2021201468A1 (en) 2021-03-25
EP4421177A2 (en) 2024-08-28
PT2970398T (pt) 2024-06-07
HUE067333T2 (hu) 2024-10-28
US20240018193A1 (en) 2024-01-18
AU2021201468B2 (en) 2022-11-24
US20220002351A1 (en) 2022-01-06
PL2970398T3 (pl) 2024-09-16
MX2015013065A (es) 2016-06-06
WO2014160463A8 (en) 2015-10-08
RU2021132097A (ru) 2022-03-03

Similar Documents

Publication Publication Date Title
HRP20240996T1 (hr) Prefuzija rsv f proteina i njihova uporaba
CN107847580B (zh) 针对rsv的疫苗
Loomis et al. Structure-based design of Nipah virus vaccines: a generalizable approach to paramyxovirus immunogen development
JP2016519658A5 (hr)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
TW201632548A (zh) 流行性感冒病毒血球凝集素之人類抗體
TWI674269B (zh) 包含免疫原性蛋白質及組合佐劑並用以誘發抗原特異性t細胞反應之疫苗組成物
JP2015500811A5 (hr)
JP2014530010A5 (hr)
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
US10766931B2 (en) Mutant fragments of OspA and methods and uses relating thereto
GB2598494A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
CN111606993A (zh) 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
CN102939101A (zh) 用于通用疫苗的流感病毒组合物和方法
Wang et al. Self-assembling ferritin nanoparticles coupled with linear sequences from canine distemper virus haemagglutinin protein elicit robust immune responses
JP2015525794A5 (hr)
RU2015106742A (ru) Композиции, содержащие химерные молекулы ospa и способы их применения
JP7372925B2 (ja) インフルエンザヘマグルチニンに対するヒト抗体
CN101991848B (zh) 猪瘟合成肽疫苗及其应用
JP2024522385A (ja) ヒトメタニューモウイルスワクチン
RU2015113230A (ru) Домен CNAB SDRE STAPHYLOCOCCUS AUREUS и его применение для вакцинации
WO2020143799A1 (zh) 广谱性中和流感病毒的全人抗体
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
CN109232737A (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP2018500879A5 (hr)